caa a22 4500 445336447 CHVBK 20180317142757.0 cr unu---uuuuu 170323e20110801xx s 000 0 eng 10.1245/s10434-011-1599-1 doi (NATIONALLICENCE)springer-10.1245/s10434-011-1599-1 Elevated Expression of the Stem Cell Marker CD133 Associated with Line-1 Demethylation in Hepatocellular Carcinoma [Elektronische Daten] [Changsong Zhang, Yun Xu, Jun Zhao, Lieying Fan, Guocheng Jiang, Rong Li, Yang Ling, Mengchao Wu, Lixin Wei] Background: The relationship of Line-1 demethylation and the CD133 expression of cancer stem cells were discussed in hepatocellular carcinoma (HCC). Methods: In 95 HCC and matched nontumor tissues, we analyzed the methylation level of Line-1 by quantitative real-time methylation-specific polymerase chain reaction, and the expression of CD133 by real-time reverse transcriptase-polymerase chain reaction and immunohistochemistry. Results: Unmethylation of Line-1 increased from nontumor tissues (1.23×107 copies/μg DNA) toward HCC tissues (2.99×107 copies/μg DNA), but methylation of Line-1 kept 2×108 copies/μg DNA around in HCC and nontumor tissues. The methylation index (MI) of Line-1 decreased from 0.919 in nontumor samples to 0.755 in HCC. Results showed that cumulative survival was significantly shorter in HCC patients with MI<0.76 than that in patients with MI≥0.76. CD133 mRNA expression were higher in HCC tissues (mean −∆Ct=−5.751) than that in nontumor tissues (mean −∆Ct=−6.742). A total of 73 (76.8%) patients had demethylation of Line-1 (∆MI<0), and 22 (23.2%) patients had hypermethylation of Line-1 (∆MI≥0). HCC with demethylation of Line-1 had elevated CD133 expression in tumor rather than matched nontumor tissues (mean −∆∆Ct=1.101), but HCC with hypermethylation of Line-1 was considered to be lower with CD133 expression in tumor (mean −∆∆Ct=−0.409). Conclusions: Line-1 hypomethylation is the most common molecular abnormality during the carcinogenic process. Elevated expression of CD133 was associated with demethylation of Line-1 in HCC. Society of Surgical Oncology, 2011 Zhang Changsong Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China aut Xu Yun Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China aut Zhao Jun Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China aut Fan Lieying Department of Clinical Laboratory, Shanghai East Hospital, Tongji University Medical School, Shanghai, China aut Jiang Guocheng Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China aut Li Rong Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China aut Ling Yang Clinical Oncology Laboratory, Changzhou Tumor Hospital, Medical College of Suzhou University, Changzhou, China aut Wu Mengchao Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China aut Wei Lixin Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China aut Annals of Surgical Oncology Springer-Verlag 18/8(2011-08-01), 2373-2380 1068-9265 18:8<2373 2011 18 10434 https://doi.org/10.1245/s10434-011-1599-1 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1599-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Zhang Changsong Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China aut NATIONALLICENCE 700 1- Xu Yun Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China aut NATIONALLICENCE 700 1- Zhao Jun Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China aut NATIONALLICENCE 700 1- Fan Lieying Department of Clinical Laboratory, Shanghai East Hospital, Tongji University Medical School, Shanghai, China aut NATIONALLICENCE 700 1- Jiang Guocheng Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China aut NATIONALLICENCE 700 1- Li Rong Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China aut NATIONALLICENCE 700 1- Ling Yang Clinical Oncology Laboratory, Changzhou Tumor Hospital, Medical College of Suzhou University, Changzhou, China aut NATIONALLICENCE 700 1- Wu Mengchao Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China aut NATIONALLICENCE 700 1- Wei Lixin Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, China aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/8(2011-08-01), 2373-2380 1068-9265 18:8<2373 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer